drugset / Trial / NCT06106945
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma
NaSequentialOpen-labelTreatment
Summary
This is a Phase I/II, modular, open-label, multicenter, dose escalation, and dose expansion/optimization study to evaluate the safety, tolerability, PK, immunogenicity, pharmacodynamics and efficacy of AZD0305 as monotherapy and in combination with other anticancer agents in participants with MM.
Timeline
- Start
- 2023-12-05
- Primary completion
- 2027-08-16
- Completion
- 2027-08-16
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AZD0305 | Unknown | — | — |
| Background | Dexamethasone | Small molecule | — | — |
| Background | Elranatamab | Monoclonal antibody | — | — |
| Background | Pomalidomide | Other / unclassified | — | — |